Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial

Phytomedicine

Volumn 22, Issue 3, 2015, Pages 394-399

  Mao, Jun J ^a   Xie, Sharon X ^a   Zee, Jarcy ^a   Soeller, Irene ^a   Li, Qing S ^a   Rockwell, Kenneth ^a   Amsterdam, Jay D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Botanical psychopharmacology; Complementary and alternative medicine; Depression; Rhodiola rosea; Sertraline

Indexed keywords

PLACEBO; RHODIOLA ROSEA EXTRACT; SERTRALINE; ANTIDEPRESSANT AGENT; PLANT EXTRACT;

ADULT; ANTIDEPRESSANT ACTIVITY; APPETITE DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE STUDY; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHODIOLA ROSEA; SENSITIVITY ANALYSIS; SEXUAL DYSFUNCTION; XEROSTOMIA; YAWNING; CHEMISTRY; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; PHYTOTHERAPY; PSYCHOLOGICAL RATING SCALE; RHODIOLA;

RHODIOLA ROSEA;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; PSYCHIATRIC STATUS RATING SCALES; RHODIOLA; SERTRALINE;

EID: 84924061282     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2015.01.010     Document Type: Article

References (32)

1. Abidov M., Crendal F., Grachev S., Seifulla R., Ziegenfuss T. Effect of extracts from Rhodiola rosea and Rhodiola crenulata (Crassulaceae) roots on ATP content in mitochondria of skeletal muscles Bull. Exp. Biol. Med. 136 2003 585 587
2. Anonymous National Institute of Mental Health. TESS (Treatment Emergent Symptom Scale - Write In) Psychopharmacol. Bull. 21 1985 1069 1072
3. Barnes P.M., Powell-Griner E., McFann K., Nahin R.L. Complementary and alternative medicine use among adults: United States, 2002 Adv. Data 343 2004 1 19
4. Beck A., Steer R., Carbin M. Psychometric properties of the Beck depression inventory: twenty-five years of evaluation Clin. Psychol. Rev. 8 1988 77 100
5. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression Arch. Gen. Psychiatry 4 1961 561 571
6. Brown R.P., Ramazanov Z. Rhodiola rosea: a phytomedicinal overview HerbalGram 56 2002 40 52
7. Bystritsky A., Kerwin L., Feusner J.D. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD) J. Altern. Complement. Med. 14 2008 175 180
8. Darbinyan V., Aslanyan G., Amroyan E., Gabrielyan E., Malmstrom C., Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression Nord. J. Psychiatry 61 2007 343 348
9. Darbinyan V., Kteyan A., Panossian A., Gabrielian E., Wikman G., Wagner H. Rhodiola rosea in stress induced fatigue - a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty Phytomedicine 7 2000 365 371
10. Elkin I., Gibbons R.D., Shea M.T., Sotsky S.M., Watkins J.T., Pilkonis P.A., Hedeker D. Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program J. Consult. Clin. Psychol. 63 1995 841 847
11. First M., Spitzer R., Gibbon M. et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/P W/PSY Screen) Institute N.Y.S.P. 2001 Biometrics Research New York, NY
12. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis J. Am. Med. Assoc. 303 2010 47 53
13. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976 US Department of Health, Education and Welfare Rockville, MD
14. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) J. Am. Med. Assoc. 289 2003 3095 3105
15. Laird N.M., Ware J.H. Random-effects models for longitudinal data Biometrics 38 1982 963 974
16. Lazarova M.B., Petkov V.D., Markovska V.L., Petkov V.V., Mosharrof A. Effects of meclofenoxate and Extr. Rhodiolae roseae L. on electroconvulsive shock-impaired learning and memory in rats Methods Find. Exp. Clin. Pharmacol. 8 1986 547 552
17. Lishmanov Iu B., Trifonova Zh V., Tsibin A.N., Maslova L.V., Dement'eva L.A. Plasma beta-endorphin and stress hormones in stress and adaptation Biull. Eksp. Biol. Med. 103 1987 422 424
18. Mao J.J., Li Q.S., Soeller I., Xie S.X., Amsterdam J.D. Rhodiola rosea therapy for major depressive disorder: a study protocol for a randomized, double-blind, placebo-controlled trial J. Clin. Trials 4 2014 170
19. Olsson E.M., von Scheele B., Panossian A.G. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue Planta Med. 75 2009 105 112
20. Panossian A., Hambardzumyan M., Hovhanissyan A., Wikman G. The adaptogens rhodiola and schizandra modify the response to immobilization stress in rabbits by suppressing the increase of phosphorylated stress-activated protein kinase, nitric oxide and cortisol Drug Target Insights 2 2007 39 54
21. Panossian A., Wikman G., Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy Phytomedicine 17 2010 481 493
22. Petkov V.D., Yonkov D., Mosharoff A., Kambourova T., Alova L., Petkov V.V., Todorov I. Effects of alcohol aqueous extract from Rhodiola rosea L. roots on learning and memory Acta Physiol. Pharmacol. Bulg. 12 1986 3 16
23. Roder C., Schaefer M., Leucht S. Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort Fortschr. Neurol. Psychiatr. 72 2004 330 343
24. ∗D report Am. J. Psychiatry 163 2006 1905 1917
25. Saratikov A.S., Lomov N.I., Syrneva N.V., Chernova N.A., Prushchep T.P., Lavrent'eva L.N., Shchipkova L.G. Physiological activity and some physico-chemical properties of acyl derivatives of pyrazolone Farmakol. Toksikol. 31 1968 437 441
26. Sayyah M., Sayyah M., Kamalinejad M. A preliminary randomized double blind clinical trial on the efficacy of aqueous extract of Echium amoenum in the treatment of mild to moderate major depression Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 166 169
27. Schrader E. Equivalence of St John's Wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression Int. Clin. Psychopharmacol. 15 2000 61 68
28. Shevtsov V.A., Zholus B.I., Shervarly V.I., Vol'skij V.B., Korovin Y.P., Khristich M.P., Roslyakova N.A., Wikman G. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work Phytomedicine 10 2003 95 105
29. van Diermen D., Marston A., Bravo J., Reist M., Carrupt P.A., Hostettmann K. Monoamine oxidase inhibition by Rhodiola rosea L. roots J. Ethnopharmacol. 122 2009 397 401
30. Walker T.B., Altobelli S.A., Caprihan A., Robergs R.A. Failure of Rhodiola rosea to alter skeletal muscle phosphate kinetics in trained men Metabolism 56 2007 1111 1117
31. Williams J.B. A structured interview guide for the Hamilton Depression Rating Scale Arch. Gen. Psychiatry 45 1988 742 747
32. Zimmermann T.M., Clouth J., Elosge M., Heurich M., Schneider E., Wilhelm S., Wolfrath A. Patient preferences for outcomes of depression treatment in Germany: a choice-based conjoint analysis study J. Affect. Disord. 148 2013 210 219